Home > Boards > Canadian > Cannabis >

Abattis Bioceuticals Corp. (ATTBF)

Add ATTBF Price Alert      Hide Sticky   Hide Intro
Moderator: Goodbuddy4863, guay, ebota12, GreenBrickRoad, N_D_K_Hey
Search This Board: 
Last Post: 1/17/2018 1:32:28 PM - Followers: 352 - Board type: Free - Posts Today: 0

Welcome to Abattis Bioceuticals Corp.

$ $ $  – Breaking NEWS –  $ $ $
Abattis Confirms Breakthrough Extraction Technology Capabilities


ATTBF – Abattis looks to become a leader in extraction with proprietary Raybot extraction technology Raybot has repurposed its industrial Preparative Chromatography Separation System, previously used in Tobacco, Pharma and Natural Food industries, specifically for implementation in the Cannabis industry.
Let us explain...

Notable Products Created with Raybot Technology:
Resveratrol | 98% purity
5-HTP | 99% purity
Ginkgo Biloba Extract | 24% purity
Inositol | 99% purity
Co-Enzyme Q10 | 98.5% purity


Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQB: ATTBF) (CSE: ATT), is a specialty biotechnology company with capabilities through its wholly-owned subsidiaries as a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets, some of which will contain cannabinoid compounds. Abattis develops and is in the process of commercializing natural health products that target ailments and satisfy important market needs. Abattis is conducting ongoing research and development to create plant-based intellectual property and ingredients. Current areas of focus are growth through acquisition and business development and cash flow through commercialization of existing assets.

Biocell Labs Inc. - is a wholly-owned subsidiary focused on providing standardized pharmaceutical-grade products. Currently, the company has 13 proprietary formulations for out-licensing to cosmetic, nutraceutical and pharmaceutical companies.

Northern Vine Labs™, a subsidiary of Abattis, seeks to become the premier analytical testing laboratory, and research and development partner to the legal cannabis industry in Canada, with existing cannabis processing, testing, and packaging facility located in Langley, British Columbia. In addition to these services, the company supports its operations by providing analytical services for Licensed Producers.

North American Bioextracts – is a retail distribution arm operating in Canada and Washington State focusing on cannabis, cannabis derivatives, and ancillary products like vaporizers. The company aims to use its proprietary extraction technologies to develop customized THC extract oils and CBD extract oils, as well as customized vaporizer flavors to enhance the end user’s experience.

Vergence Sales & Marketing Group – creates botanical formulations, medical marijuana and specialized health products for safe and effective solutions to pain caused by inflammation and mental ailments common to "modern lifestyle".

Through our divisions Biocell Labs Inc. and Vergence Sales & Marketing Group, we develop and license natural health products and have future plans to expand into the nutraceutical, pharmaceutical and cosmetic markets. The Company has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding natural health product market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions.

Within our other divisions Northern Vine, North American Bioextracts and Biocube we have capabilities that support the production and extraction of botanical ingredients for our products; one of which includes cannabis.

For more information, visit the Company's website at: Executive Overview (PDF download file)

Our investors are forward thinkers in the emerging bioceutical and medical marijuana markets. We are a specialty, vertically-integrated biotechnology company that aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. From patented and proprietary formulations, extraction and processing methods, Abattis consistently seeks opportunities to participate in varied markets all connected by a common global purpose and customer base: seeking health through natural products.
Abattis is uniquely positioned to fully exploit the growing trend toward marijuana legalization in the United States and medicinal use in Canada as licensed and international jurisdictions.

“Health Canada estimates that the emerging medical marijuana market to be in excess of $1 billion.
Stephen Easton, an SFU Economist, estimated that nationally the Cannabis industry generates approximately $19 to $21 billion”

We develop and license natural health products with unique botanical blends, CBD and proprietary ingredients. These infused food and beverage brands are designed for wellness nutraceuticals, medical foods & botanical drugs market with future plans to expand into the pharmaceutical and cosmetic markets.

Canada’s cannabis industry is expected to surpass $22 billion in size over the coming years, according to Deloitte, with over 140,000 registered medical marijuana patients today. With about 40 licensed producers under the ACMPR, the industry is expected to see a shortfall in supply given the 205% compound annual growth rate in registered patients since June of 2014 along with the near-term plans to legalize marijuana for recreational use.

Northern Vine Labs™ is getting ready for our launch.

Visit our website and join our community for updates and educational information.


Northern Vine Labs™ are now on Health Canada list for licensed dealers!
The following link shows a list of laboratories that have a current Dealers Licence under the Narcotic Control Regulations and who are licensed to conduct activities with cannabis:

Northern Vine Labs™, a subsidiary of Abattis, seeks to become the premier analytical testing laboratory, and research and development partner to the legal cannabis industry in Canada. The ability to legally work with Cannabis remains rare and highly specialized. Northern Vine Labs™ Controlled Substance License enables proprietary methods and services to be offered to currentlicensed producers within Canada’s existing Federal regulatory structure. It also offers Northern Vine Labs™ customers, including Abattis, the ability to formulate and develop new products containing cannabinoid ingredients in advance of the end to prohibition.


In partnership with the BC Institute of Technology (BCIT), Northern Vine Labs™ has been working to develop new and improved methods for the analysis of cannabis. This work is expected to be published by BCIT positioning NV Labs as the industry expert in analytical services which are substantially faster and more reliable than any other in Canada. Utilizing these proprietary methods, Northern Vine Labs will offer for sale its analytical reference standards enabling market participants to check quality and metrological traceability of products, to validate analytical measurement methods, and/or to support the proper calibration of instruments.
Northern Vine Labs™ operations under the CSL will include:
1. Analytical Services
2. Research and Development Services
3. Extraction to Support Analysis and R&D?
In future, NV Labs anticipates the opportunity to amend its license to include:
4. Extraction service for sale of extracted ingredients
5. Importation/Exportation

Analytical Services
Potency Testing Determining composition and concentration of various cannabinoid compounds
Moisture Analysis and Foreign Matter Testing
Microbiological Testing
Ensuring the safety of products by testing for levels of mold and bacteria.

The Cannabis Trade Alliance of Canada, which represents producers, said the new regime should provide for mandatory testing: 

“Mandatory laboratory testing of all cannabis products (potency and contaminants) – a critical step in the seed-to-sale process when considering public health, and should be the main objective in the legalized framework.”


Vergence Visionary Bioceuticals, a subsidiary of Abattis, is a team of nutraceutical marketing and brand specialists focused on innovative health products to penetrate the fast growing market for natural, safe and effective solutions to two of society’s unresolved and ubiquitous health issues: Pain caused by inflammation and mental ailments common to our modern lifestyle. Vergence is the exclusive exporter of 99.6%, organic and pure CBD Isolate out of Hong Kong and directly to the rest of the world. Together with a vast distribution network and custom product and branded formulations via Northern Vine Labs, Vergence aims to promote healthy living through natural remedies. Vergence is in possession of over 100 Natural Product Numbers (NPN's) as granted by Health Canada and plans to develop and distribute these products into global markets for end use.

Canada’s cannabis industry is projected to reach C$22.6 billion over the coming years, according to Deloitte analysts, driven by the legalization of recreational cannabis next year. While many licensed producers are focused on expanding capacity, the best opportunities may be those that can add value for existing licensed producers. These opportunities include those companies focused on higher value cannabis extracts. Read here why the proprietary extraction technology from Abattis represents an important breakthrough that investors shouldn’t ignore.

Chart source: The Value Case For Investing In The Cannabis Sector
Goldman Small Cap Research report, 'This Stock Set to Double Thanks to New License'
Abattis Bioceuticals Corp. - Stock Up Big on Recent News, Greater Gains on Horizon (October 20, 2016).

Goldman Small Cap Research report 
'The Next Industry-Changing Specialty Health Stock'
Abattis Bioceuticals Corp. - Major Revenue Ahead for Innovative, Diversified Bioceuticals Pioneer (June 13, 2016).

There are an unlimited number of common shares without par value authorized for issue.

Issued & Outstanding (10/08/2017)The Company has 167,580,301 common shares issued and outstanding (source)

System for Electronic Document Analysis and Retrieval (SEDAR) -


Abattis Bioceuticals Corporation
Address: 104 - 9295 198th Street | Langley, BC V1M 3J9 | Canada

As an investor, you are our partner and we take this relationship seriously.
Please contact us if you have any questions or if you would like to invest in Abattis

Brook Bellian | Corporate Communications (778) 883.7869 |


Abattis Bioceuticals
Phone: (604) 336.0881

Northern Vine
(604) 336.0881 | (604) 371.3371 | (604) 888.1129

CHINA | Dr. Shuang Xie  Ph. D.
Suzhou Raybot Material Tech Ltd
T: 17785884380 | C: 17783175968
Phone: 86 5125240581 | 8613901388668
Address:  No. 10-1 Yang Yuan Road,
Xinzhuang Zhen,Changshu | China


22/12/2017 | Abattis Announced its Intent to Purchase Green Tree Therapeutics
18/12/2017 | Abattis Abattis Announces Expansion of Northern Vine Dealer’s License
12/12/2017 | Abattis Confirms Breakthrough Extraction Technology Capabilities
12/12/2017 | Abattis Successfully Closes Private Placement
11/06/2017 | Abattis Validates Lab Strategy, Sets Stage for Rapid Growth
11/01/2017 | Emerald Health Expands Capabilities with Northern Vine Labs Deal
10/26/2017 | Abattis Partnership with Emerald Health Therapeutics
10/19/2017 | Abattis Announces Private Placement
10/04/2017 | Abattis Strikes South Korea Distribution
09/20/2017 | Abattis Prepares for Growth in Extracts
09/15/2017 | Share Swap – Abattis Regain 100% Control Over Northern Vine
09/13/2017 | Important Update on Northern Vine and Sales Division
08/28/2017 | Breakthrough CBD-Based Sunscreen Formulation
08/23/2017 | Northern Vine Provides Update on Growth Targets
08/21/2017 | EXPERION Becoming Legal Cannabis Producer
08/11/2017 | Abattis Adds New Product Line to Subsidiary Vergence
08/09/2017 | Abattis Files Amended and Restated Financial Statements
07/25/2017 | Abattis Expands Its Asian Distribution Sales Channels
07/17/2017 | Abattis Obtains DTC Eligibility
07/15/2017 | Abattis Partners with the CSE & Stockpools
06/15/2017 | New Key Executive and Management Positions
06/13/2017 | Abattis Provides Company Update
06/07/2017 | Abattis Announces New Board Members
05/10/2017 | Northern Vine Labs Expands Its Sales Team
05/03/2017 | Official Launch of Northern Vine Laboratory
04/26/2017 | Abattis Signed Exclusive Destribution Agreement
04/10/2017 | Abattis Bioceuticals Announces New CEO
04/06/2017 | Abattis Gets Added to the Marijuana Index by MJIC
04/04/2017 | Near-term Legalization Puts Testing into Focus
03/27/2017 | Next Month - Legislation to Legalize Marijuana in CA
03/20/2017 | Dr. David Galvez - New Science Advisor of Northern Vine
03/13/2017 | Abattis Team Positions for Next Stage of Growth
03/07/2017 | LP Highlights Continued Need for Testing
02/24/2017 | Abattis Prepares to Launch Northern Vine Labs
02/24/2017 | Abattis Annual Report - September 30, 2016
02/14/2017 | Abattis Audit Update
02/08/2017 | Key Shortcomings in Canada's Cannabis Industry
02/03/2017 | Abattis Audit Update
12/16/2016 | Abattis Provides Corporate Update
12/09/2016 | $ 5 Million Facility with Aluminia Partners
11/15/2016 | Dr. Shuang Xie – Director and CTA
11/09/2016 | Licensing Deal and Brand Acouisition
11/07/2016 | Renewal of Health Canada Licence
11/02/2016 | Appointment of New Independent Director
10/24/2016 | Agreement to Acquire 100% of Experion
10/17/2016 | Experion Prepares for Construction
10/05/2016 | MOU with Global Damon Pharma of South Korea
10/03/2016 | Northern Vine Receives Controlled Substance Licence

If you want to add or to change something on this site - send a message to guay.
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#31517  Sticky Note Abattis Announces LOI for Partnership with Alliance of GreenBrickRoad 01/09/18 10:05:18 AM
#31025  Sticky Note Abattis Successfully Closes Private Placement: Goodbuddy4863 12/12/17 07:44:20 PM
#30886  Sticky Note Abattis Confirms Breakthrough Extraction Technology Capabilities guay 12/12/17 12:05:39 PM
#26399  Sticky Note Corporate Update ebota12 11/05/15 07:31:44 PM
#12064  Sticky Note BOARD WARNING - Please Read: IH Admin [Shelly] 06/09/14 01:18:32 PM
#31669   OK thanks. I hardly ever go on FB. debrojo 01/17/18 01:32:28 PM
#31668   It was on stockhouse and also the Facebook Lvannoy88 01/17/18 01:30:31 PM
#31667   Curious what other board you found? the only debrojo 01/17/18 01:26:48 PM
#31666   Thanks...makes me wonder if he holds similar positions steadykickin 01/17/18 11:27:11 AM
#31665   I'd guess William Panenka sits in on product GreenBrickRoad 01/17/18 11:23:17 AM
#31664   He is an "Independent Director" correct. What expertise/ steadykickin 01/17/18 11:15:41 AM
#31663   *PRODUCT FEEDBACK* I ordered the ALOE from Abattis PurSuitOfHappyness 01/17/18 10:48:46 AM
#31662   yeah that's SUPER frustrating Lvannoy88 01/17/18 10:25:23 AM
#31661   Geez, William Panenka is a leaky faucet. If GreenBrickRoad 01/17/18 10:16:18 AM
#31660   where we going today? Sideways or UP??? Lvannoy88 01/17/18 08:52:28 AM
#31659   Thanks. sante1 01/17/18 06:45:44 AM
#31658   For something a bit more up to date Irontank 01/17/18 04:43:31 AM
#31657 sante1 01/17/18 03:37:56 AM
#31656   I think some of those investors may have Irontank 01/16/18 06:19:20 PM
#31655   Thanks sante1 01/16/18 04:25:23 PM
#31654   Yup sideways trading for the next little while dragon_warrior 01/16/18 04:23:17 PM
#31653   Yep. And I think it’s gonna take Lvannoy88 01/16/18 04:16:21 PM
#31652   You called it. I had the same feeling, GreenBrickRoad 01/16/18 02:49:24 PM
#31651   I’d’s still working out...’ Lvannoy88 01/16/18 02:06:53 PM
#31650   Has anyone any idea how this worked out sante1 01/16/18 01:58:49 PM
#31649   Hi la, BIGKAHUNA57 01/16/18 12:09:41 PM
#31648   $$$$$$$$$ Buy the DIPS $$$$$$$$$$$ Going to be Mullery 01/16/18 12:07:54 PM
#31647   Kahuna- Where are the revenue and earnings numbers? la_ltrader 01/16/18 12:01:06 PM
#31646   I don't post much here, but read daily. BIGKAHUNA57 01/16/18 10:29:56 AM
#31645   No doom and gloom...I want up and up brother Lvannoy88 01/16/18 10:01:51 AM
#31644 steadykickin 01/16/18 09:57:19 AM
#31643   Had to match Canada from yesterday. Unfortunately Lvannoy88 01/16/18 09:48:05 AM
#31642   At least nice rise...;) Maschiman 01/16/18 09:46:11 AM
#31641   I hate market holidays...however I do love watching Lvannoy88 01/16/18 08:04:47 AM
#31640   Thanks have a nice trading day. Personal I sante1 01/16/18 01:30:30 AM
#31639   Pretty much, yep. First day of trading being GreenBrickRoad 01/15/18 10:57:31 PM
#31638   I fully agree with that but isn't it sante1 01/15/18 06:11:45 PM
#31637   Actually, I agree with much of what you GreenBrickRoad 01/15/18 05:36:15 PM
#31636   See my post 31623!!! (2 days ago!) I sante1 01/15/18 04:29:38 PM
#31635   I most certainly hope you are correct! BUT 1GraveUndertaker 01/15/18 04:25:59 PM
#31634   The accusations made against Abenante ... I doubt 1GraveUndertaker 01/15/18 04:19:51 PM
#31633   sorry...its $150K USD...from what I read. And Lvannoy88 01/15/18 03:08:43 PM
#31632   OK thanks. Does that mean you have to debrojo 01/15/18 03:02:41 PM
#31631   no...but on another board I saw they require Lvannoy88 01/15/18 02:54:08 PM
#31630   Did you ever hear anything back from them debrojo 01/15/18 02:50:46 PM
#31629   up 10% on Canadian side today....hopefully translates to Lvannoy88 01/15/18 02:46:02 PM
#31628   And Abattis climbed significantly since September when the QuidRunner 01/15/18 01:15:36 PM
#31627   We discussed that a long time ago in GreenBrickRoad 01/15/18 12:27:33 PM
#31626   Any predictions on tomorrow? Any chance of QuidRunner 01/15/18 11:32:57 AM
#31625   Fidelity just looked, shows 230,300,000 shares outstanding rockman13 01/14/18 08:28:53 PM
#31624   Every time I think I have ATTBF figured Penny Masters 01/14/18 07:00:43 PM
#31623   What's your opinion? In my believe the candlestick sante1 01/14/18 03:13:38 PM
#31622   What's your opinion? In my believe the candlestick sante1 01/14/18 03:08:18 PM
#31621   This is a lawsuit built on BS....they are Lvannoy88 01/14/18 10:51:23 AM
#31620   If this is a problem for Abattis, the PurSuitOfHappyness 01/14/18 06:15:41 AM